Tacrolimus and cyclosporine A show similar efficacy in long-term survival and relapse reduction in AML post-transplant patients. No significant differences were found in leukemia-free survival, ...
Ruxolitinib was recently approved to treat acute graft-versus-host disease (GVHD), and trials are ongoing to understand the best way to use the treatment with transplantation, said David Snyder, MD, ...
Please provide your email address to receive an email when new articles are posted on . Vedolizumab showed greater efficacy than placebo when added to standard prophylaxis for prevention of lower ...
A major drawback to the use of alloHCT, a curative treatment, in patients with AML are the associated toxicities including GVHD. This study presents a protocol that aims to maximize the effect of ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved abatacept in combination with a calcineurin inhibitor and methotrexate for prevention of acute ...
While stem cell transplantation is a transformative therapy for many cancer patients, acute graft-versus-host-disease (GVHD) remains a major, life threatening complication experienced by many. Acute ...
RLS-0071 is an investigational peptide that has been shown to inhibit neutrophil-mediated inflammation. The Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations to ...
Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (GVHD) finally reached the FDA green light. The ...
Acute graft-vs-host disease (GVHD) is a potentially deadly complication after allogeneic hematopoietic stem cell transplant (HSCT), occurring in 30% to 50% of patients within 100 days of transplant. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results